For the interim period of the fiscal year ending March 2027, net sales were 5,097 million yen (Year-over-Year +0.8%), operating income was 478 million yen (-29.3%), ordinary income was 474 million yen (-29.7%), and interim net income was 368 million yen (-28.0%). Full-year outlook is maintained as previously announced. Dividends plan continues through the end of the second quarter, with a full-year dividend forecast of 20 yen. Financial position remains stable with a capital adequacy ratio of 71.5% and total assets of 10,915 million yen; further details follow in the main text.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7775","jir_company_name":"Daiken Medical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/7775-20261029-01.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, net sales were 5,097 million yen (Year-over-Year +0.8%), operating income was 478 million yen (-29.3%), ordinary income was 474 million yen (-29.7%), and interim net income was 368 million yen (-28.0%). Full-year outlook is maintained as previously announced. Dividends plan continues through the end of the second quarter, with a full-year dividend forecast of 20 yen. Financial position remains stable with a capital adequacy ratio of 71.5% and total assets of 10,915 million yen; further details follow in the main text.","jir_summary":"### Overview of Performance\nFor the interim period of the fiscal year ending March 2027, Daiken Medical Co., Ltd. recorded net sales of 5,097 million yen (Year-over-Year +0.8%). Despite a slight increase in revenue, operating income declined significantly to 478 million yen (-29.3%) due to rising material costs and higher personnel expenses. Ordinary income was 474 million yen (-29.7%), and interim net income was 368 million yen (-28.0%), with key profit indicators falling below the prior-year period.\n\n### Financial Position and Dividends\nTotal assets are approximately 10,915 million yen, net assets are 7,829 million yen, and the capital adequacy ratio remains at 71.5%, maintaining a stable financial base. There is no revision to the recently announced dividend forecast; the company continues to plan an annual dividend of 20 yen, including a year-end dividend of 11 yen.","jir_financial_highlights":"Net Sales: 5,097 (Year-over-Year +0.8%)\nOperating Income: 478 (Year-over-Year -29.3%)\nOrdinary Income: 474 (Year-over-Year -29.7%)\nInterim Net Income: 368 (Year-over-Year -28.0%)\nTotal Assets: 10,915 (Year-over-Year Unknown (interim))\nNet Assets: 7,829 (Year-over-Year + Unknown)\nCapital Adequacy Ratio: 71.5 (Year-over-Year)","jir_category":"","jir_hashtags":"#DaikenMedical, #Earnings, #InterimResults","jir_key_figures":"Net Sales: 5,097 million yen (Year-over-Year +0.8%)\nOperating Income: 478 million yen (Year-over-Year -29.3%)\nInterim Net Income: 368 million yen (Year-over-Year -28.0%)","jir_meta_title":"Daiken Medical Co., Ltd. \u2014 FY2027 2Q Results | Net Sales 5,097 million yen, Operating Income 478 million yen","jir_meta_description":"Key points of Daiken Medical Co., Ltd.'s FY2027 second quarter financial summary. Net sales: 5,097 million yen; Operating income: 478 million yen. Full-year outlook unchanged; dividend forecast 20 yen. Capital adequacy ratio 71.5%; net assets 7,829 million yen.","jir_og_title":"Daiken Medical Co., Ltd. \u2014 FY2027 2Q Results | Net Sales 5,097 million yen, Operating Income 478 million yen","jir_og_description":"Daiken Medical Co., Ltd.'s interim results: net sales 5,097 million yen, operating income 478 million yen. Full-year outlook unchanged; dividend forecast 20 yen. Financial position remains stable.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58413,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136963","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n